	US 12,280,105 B2
	Compositions and methods of mRNA vaccines against novel coronavirus infection
Neeti Ananthaswamy, Gaithersburg, MD (US); Yong-Sik Bong, Gaithersburg, MD (US); David Brown, Gaithersburg, MD (US); Renxiang Chen, Gaithersburg, MD (US); Ju Hyeong Jeon, Gaithersburg, MD (US); Zhifeng Long, Gaithersburg, MD (US); Dong Shen, Baltimore, MD (US); Chun Lu, Montreal (CA); Patrick Y. Lu, Potomac, MD (US); Shenggao Tang, Guangzhou (CN); Jiaxi He, Guangzhou (CN); and Ziyang He, Potomac, MD (US)
Assigned to RNAIMMUNE, INC., Gaithersburg, MD (US)
Filed by RNAimmune, Inc., Gaithersburg, MD (US)
Filed on Feb. 9, 2024, as Appl. No. 18/438,342.
Application 18/438,342 is a continuation of application No. PCT/US2022/039997, filed on Aug. 10, 2022.
Claims priority of provisional application 63/232,101, filed on Aug. 11, 2021.
Prior Publication US 2024/0226275 A1, Jul. 11, 2024
Int. Cl. A61K 39/215 (2006.01); A61K 9/1271 (2025.01); A61P 37/04 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [A61K 9/1271 (2013.01); A61P 37/04 (2018.01); C07K 14/005 (2013.01); A61K 2039/53 (2013.01); C12N 2770/18022 (2013.01); C12N 2770/18034 (2013.01)]

30 Claims

1. A ribonucleic acid (RNA) encoding a spike(S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the S protein or immunogenic fragment thereof comprises the polypeptide of SEQ ID NO: 5, the polypeptide of SEQ ID NO: 6, the polypeptide of SEQ ID NO: 7, the polypeptide of SEQ ID NO: 10, the polypeptide of SEQ ID NO: 11, or the polypeptide of SEQ ID NO: 14.